concept

ALPHA-SYNUCLEIN AGGREGATION

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about ALPHA-SYNUCLEIN AGGREGATION: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

37Connections

4Hypotheses

5Analyses

13Outgoing

24Incoming

0Experiments

5Debates

No summary available yet.

View on Wiki →

No AI portrait yet

💡 Concept Info

Name	ALPHA-SYNUCLEIN AGGREGATION

Pathway Diagram

graph TD
    ALPHA_SYNUCLEIN_AGGREGATION["ALPHA-SYNUCLEIN AGGREGATION"]
    ALPHA_SYNUCLEIN_AGGREGATION -->|"causes"| Parkinson_s_Disease["Parkinson's Disease"]
    ALPHA_SYNUCLEIN_AGGREGATION -->|"causes"| Neurodegeneration["Neurodegeneration"]
    ALPHA_SYNUCLEIN_AGGREGATION -->|"causes"| CNS_Inflammation["CNS Inflammation"]
    ALPHA_SYNUCLEIN_AGGREGATION -->|"interacts"| Mitochondrial_Dysfunction["Mitochondrial Dysfunction"]
    Short_Chain_Fatty_Acids["Short-Chain Fatty Acids"] -->|"modulates"| ALPHA_SYNUCLEIN_AGGREGATION
    BMAL1["BMAL1"] -->|"promotes"| ALPHA_SYNUCLEIN_AGGREGATION
    Piperine["Piperine"] -->|"inhibits"| ALPHA_SYNUCLEIN_AGGREGATION
    ceftriaxone["ceftriaxone"] -->|"inhibits"| ALPHA_SYNUCLEIN_AGGREGATION
    Polyamines["Polyamines"] -->|"modulates"| ALPHA_SYNUCLEIN_AGGREGATION
    Ceftriaxone["Ceftriaxone"] -->|"inhibits"| ALPHA_SYNUCLEIN_AGGREGATION
    SNCA["SNCA"] -->|"involved_in"| ALPHA_SYNUCLEIN_AGGREGATION

Outgoing (13)

Target	Relation	Type	Str
Parkinson's Disease	causes	disease	0.95
Parkinson's Disease	associated_with	disease	0.95
Mitochondrial Depolarization	causes	phenotype	0.93
Dopaminergic Neurons	causes	cell_type	0.92
Parkinson's Disease	causes	disease	0.90
ATP Production	downregulates	phenotype	0.90
Autophagy-Lysosomal Pathway	involved_in	pathway	0.90
microtubule destabilization	drives	process	0.90
Parkinson's Disease	contributes_to	disease	0.90
Mitochondrial Fragmentation	causes	phenotype	0.89
CNS Inflammation	causes	process	0.85
dopaminergic neuron loss	contributes_to	phenotype	0.85
Neurodegeneration	causes	process	0.85

Incoming (24)

Source	Relation	Type	Str
SNCA	involved_in	gene	0.95
SNCA	causes	gene	0.90
Piperine	inhibits	compound	0.90
D-520	suppresses	drug	0.90
BMAL1	promotes	gene	0.90
lysosomal dysfunction	causes	mechanism	0.90
autophagy	prevents	pathway	0.90
Short-Chain Fatty Acids	modulates	compound	0.90
SNCA	regulates	gene	0.85
BMAL1	inhibits	gene	0.85
ceftriaxone	inhibits	drug	0.85
SNCA	involved_in	protein	0.80
gut microbiota	promotes	process	0.80
neuroinflammation	promotes	process	0.80
Polyamines	modulates	compound	0.80
Ceftriaxone	inhibits	drug	0.80
SCFAS	inhibits	compound	0.80
Ferroptosis	modulates	process	0.70
iron	causes	biomarker	0.70
curli fibrils	causes	biomarker	0.70
Dorsal Motor Nucleus of the Vagus Nerve	associated_with	cell_type	0.70
Olfactory Bulb	associated_with	cell_type	0.70
propionate	modulates	pathway	0.50
Curli fibrils	causes	protein	0.50

Targeting Hypotheses (4)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
m6A-dependent control of alpha-synuclein transcript fate and	0.626	neurodegeneration	m6A RNA Modification and Alpha-Synuclein
Cell-state stratification is required to resolve m6A RNA Mod	0.612	neurodegeneration	m6A RNA Modification and Alpha-Synuclein
Perturbation-first validation should precede therapeutic cla	0.608	neurodegeneration	m6A RNA Modification and Alpha-Synuclein
Glucosylceramide accumulation nucleates alpha-synuclein aggr	0.525	Parkinson's disease	GBA-Synuclein Loop Therapeutics for PD